title: Cost-effectiveness analysis of ziprasidone versus haloperidol in sequential intramuscular/oral treatment of exacerbation of schizophrenia: economic subanalysis of the ZIMO trial.
abstract: OBJECTIVE
  This study aimed to assess the cost effectiveness of ziprasidone versus haloperidol in sequential intramuscular (IM)/oral treatment of patients with exacerbation of schizophrenia in Spain.
  
  
  METHODS
  A cost-effectiveness analysis from the hospital perspective was performed. Length of stay, study medication and use of concomitant drugs were calculated using data from the ZIMO trial. The effectiveness of treatment was determined by the percentage of responders (reduction in baseline Brief Psychiatric Rating Scale [BPRS] negative symptoms subscale >or=30%). Economic assessment included estimation of mean (95% CI) total costs, cost per responder and the incremental cost-effectiveness ratio (ICER) per additional responder. The economic uncertainty level was controlled by resampling and calculation of cost-effectiveness acceptability curves.
  
  
  RESULTS
  A total of 325 patients (ziprasidone n = 255, haloperidol n = 70) were included in this economic subanalysis. Ziprasidone showed a significantly higher responder rate compared with haloperidol (71% vs 56%, respectively; p = 0.023). Mean total costs were euro3582 (95% CI 3226, 3937) for ziprasidone and euro2953 (95% CI 2471, 3436) for haloperidol (p = 0.039), mainly due to a higher ziprasidone acquisition cost. However, costs per responder were lower with ziprasidone (euro5045 [95% CI 4211, 6020]) than with haloperidol (euro5302 [95% CI 3666, 7791], with a cost per additional responder (ICER) for ziprasidone of euro4095 (95% CI -130, 22 231). The acceptability curve showed an ICER cut-off value of euro13 891 at the 95% cost-effectiveness probability level for >or=30% reduction in BPRS negative symptoms.
  
  
  CONCLUSIONS
  Compared with haloperidol, ziprasidone was significantly better at controlling psychotic negative symptoms in acute psychoses. The extra cost of ziprasidone was offset by a higher effectiveness rate, yielding a lower cost per responder. In light of the social benefit (less family burden and greater restoration of productivity), the incremental cost per additional responder with sequential IM/oral ziprasidone should be considered cost effective in patients with exacerbation of schizophrenia in Spain.
authors: Department of Psychiatry, Hospital Rodríguez Lafora, Madrid, Spain.
authors: Fernando
authors: F
authors: Cañas
authors: Víctor
authors: V
authors: Pérez-Solá
authors: Silvia
authors: S
authors: Díaz
authors: Javier
authors: J
authors: Rejas
mesh_terms: D000284:Administration, Oral; D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000191:economics*; D010054:Brief Psychiatric Rating Scale; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004359:Drug Therapy, Combination; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage* / Q000191:economics*; D017721:Hospital Costs; D006801:Humans; D007273:Injections, Intramuscular; D007902:Length of Stay / Q000191:economics; D008297:Male; D010879:Piperazines / Q000008:administration & dosage* / Q000191:economics*; D011788:Quality of Life; D012107:Research Design; D012559:Schizophrenia / Q000188:drug therapy* / Q000191:economics*; D013030:Spain; D013844:Thiazoles / Q000008:administration & dosage* / Q000191:economics*; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D013844:Thiazoles; C092292:ziprasidone; D006220:Haloperidol
references: Gen Hosp Psychiatry. 2005 Mar-Apr;27(2):140-4
references: 15763126
references: Lancet. 2004 Jun 19;363(9426):2063-72
references: 15207959
references: N Engl J Med. 2003 Oct 30;349(18):1738-49
references: 14585943
references: J Neuropsychiatry Clin Neurosci. 2000 Spring;12(2):257-64
references: 11001606
references: Eur J Pharmacol. 2001 Aug 17;425(3):197-201
references: 11513838
references: Acta Psychiatr Scand. 1997 Oct;96(4):265-73
references: 9350955
references: Soc Psychiatry Psychiatr Epidemiol. 2004 Jul;39(7):507-13
references: 15243687
references: Arch Gen Psychiatry. 1997 Jun;54(6):549-57
references: 9193196
references: Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003079
references: 16235313
references: J Clin Psychiatry. 2001 Jan;62(1):12-8
references: 11235922
references: J Ment Health Policy Econ. 2001 Mar 1;4(1):25-34
references: 11967463
references: Arch Gen Psychiatry. 1991 Mar;48(3):239-46
references: 1671741
references: Ann Clin Psychiatry. 2004 Jul-Sep;16(3):145-54
references: 15517847
references: Am J Health Syst Pharm. 2002 Sep 1;59(17 Suppl 5):S4-11
references: 12227084
references: J Clin Psychiatry. 2005 Sep;66(9):1122-9
references: 16187769
references: J Psychiatry Neurosci. 1993 Jan;18(1):18-23
references: 8461276
references: Schizophr Res. 1999 May 4;37(1):13-20
references: 10227104
references: Can J Psychiatry. 1999 Jun;44(5):464-72
references: 10389607
references: Lancet. 1999 Jul 10;354(9173):111-5
references: 10408486
references: Acta Psychiatr Scand Suppl. 2006;(429):60-3
references: 16445484
references: Eur Psychiatry. 2005 Aug;20(5-6):386-94
references: 16171653
references: J Abnorm Psychol. 1998 May;107(2):355-9
references: 9604565
references: J Clin Psychiatry. 2003;64 Suppl 19:13-8
references: 14728085
references: Psychopharmacology (Berl). 1998 Nov;140(2):173-84
references: 9860108
references: Soc Psychiatry Psychiatr Epidemiol. 1997 Feb;32(2):104-8
references: 9050352
references: Schizophr Bull. 1994;20(3):557-66
references: 7973471
references: Biol Psychiatry. 1997 Aug 15;42(4):233-46
references: 9270900
references: Acta Psychiatr Scand. 1996 Aug;94(2):118-24
references: 8883573
references: Online J Issues Nurs. 2004 Nov 29;10(1):7
references: 15727542
references: Psychopharmacology (Berl). 2005 Apr;178(4):514-23
references: 15650846
references: Acta Psychiatr Scand. 1999 Nov;100(5):359-66
references: 10563453
references: CNS Drugs. 2002;16(4):219-28
references: 11945106
references: J Clin Psychiatry. 2000 Dec;61(12):933-41
references: 11206599